Ascendis Health, the health and consumer products firm, announced a delisting offer at R0.97 per share, approved by 93% of shareholders. The deal, funded by internal resources and RMB loan, closes December 2025 if conditions met. Shares trade ex-offer from 28 November. Delisting allows faster acquisitions without JSE scrutiny.
Click here to read the SENS